NCT03231800View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG

dasotraline

dasotraline 2mg capsule once daily

DRUG

Placebo

Placebo capsule once daily

Trial Locations (8)

32751

Meridien Research, Maitland

33134

Qps-Mra, Llc, South Miami

34201

Meridien Research, Bradenton

77007

Bayou City Research, Ltd, Houston

84015

Ericksen Reasearch and Development, Clinton

89128

Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas

92660

Avida Inc, Newport Beach

02043

South Shore Psychiatric Services PC, Hingham

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03231800 - A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. | Biotech Hunter | Biotech Hunter